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Abstract 
The prevalence of hyperlipidemia, along with other non-communicable diseases, 
is on the rise in low- and middle-income countries.  Given the resource-limited setting, a 
myriad of diagnostic challenges exist with traditional laboratory-based lipid tests, 
including mobility, timeliness, and laboratory infrastructure.  Novel technology in the 
form of “point of care” devices seeks to overcome such barriers by providing immediate 
results without dependency on significant laboratory infrastructure.  CardioChek PA 
(Polymer Technology Systems, Inc., Indianapolis, United States) is a point of care lipid 
measuring device and is readily available in Kenya.  However, it has not been validated 
in this setting.  In this study, I assess the accuracy of CardioChek PA with respect to 
standard laboratory-based testing, which is currently the gold standard.   
In Webuye, Kenya, two blood samples were collected from 246 subjects to 
simultaneously measure the lipid levels via both CardioChek PA and the gold standard.  
All subjects were adults, and geographic stratified sampling methods were applied.  
Statistical analysis of the novel device’s accuracy was based on percent bias, which is the 
standardized approach established by the National Cholesterol Education Program 
(NCEP) of the National Institute of Health (NIH). The NCEP suggests that percent bias 
be ≤±3% for low-density lipoprotein (LDL) cholesterol, ≤±5% for high-density lipoprotein 
  
v 
(HDL) cholesterol, ≤±5% for total cholesterol (TC), and ≤±4% for triglycerides (TG).   
Misclassification rates and absolute percent bias were also analyzed. 
This study found the CardioChek PA analyzer to be substantially inaccurate for 
LDL cholesterol (-25.9% bias), HDL cholesterol (-8.2% bias), and TC (-15.9% bias).  For 
TG, the CardioChek PA performed well with a percent bias of 0.03%. However, the TG 
absolute percent bias (27.7%) and proportion of patients outside of the NCEP range 
(85%) reflected substantial inaccuracy of measurements.  Moreover, those patients at 
higher risk of complications from hyperlipidemia were most likely to be misclassified 
into a lower risk category.  Thus, we conclude that CardioChek PA is inaccurate and not 
suitable for our clinical setting.  Furthermore, the findings highlight the need to validate 
new diagnostic tools in the appropriate setting prior to scale up regardless of its 
potential for novel utility.  
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1. Introduction  
Novel methods of healthcare delivery are being sought to tackle the rising 
burden of non-communicable diseases (NCDs) in low- and middle-income countries 
(LMICs) 1.  More specifically, cardiovascular disease deserves heightened attention given 
its position as the leading NCD contributing to mortality.  In addition, its myriad of 
modifiable risk factors require discrete interventions 2.  Hyperlipidemia, diabetes 
mellitus, hypertension, smoking, and obesity are just a few of these risk factors that 
demand primary and secondary prevention measures.  In LMICs, point of care (POC) 
diagnostics have long been proposed as a potentially worthwhile avenue for 
overcoming many of the barriers to diagnostic care, including mobility, timeliness, and 
laboratory infrastructure.  For diabetes, POC diagnostics for measuring real-time blood 
sugar levels, as well as average blood sugar levels over the past three months, have 
facilitated the process of screening for undiagnosed patients and monitoring those who 
are already diagnosed 3, 4.  Unfortunately, hyperlipidemia does not possess an 
established, formidable equivalent in terms of real-time diagnostic technology. 
1.1 The rise of non-communicable diseases and hyperlipidemia 
Non-communicable diseases are usually thought of as chronic illnesses that are 
not due to transmission of an infectious pathogen and often share similarities in terms of 
common risk factors.  Examples of NCDs include high cholesterol, cancer, heart disease, 
and diabetes mellitus.  Historically, infectious diseases were thought to be 
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predominantly diseases of resource-limited countries, and NCDs were seen as diseases 
of the affluent.  However, the WHO reported in 2010 that NCDs already superseded 
communicable, or infectious, diseases to become the top cause of mortality in LMICs 2.  
Among NCDs, cardiovascular disease alone was reported to cause 48% (17 million) of all 
NCD deaths in 2008.   
The rising trend in NCD prevalence and incidence is compounded by the 
alarming economic ramifications.  In a 2008 study assessing the economic burden of 
NCDs, a projected $84 million in healthcare resources would be lost due to heart disease, 
diabetes, and stroke alone between 2006 and 2015 5.  These findings have resulted in a 
need for reassessing the global health community’s approach to healthcare delivery 1, 6.   
Specifically, hyperlipidemia is an NCD which merits attention given its direct 
relationship with morbid cardiovascular diseases, such as heart attack and stroke.  
Hyperlipidemia is an abnormal elevation of the naturally occurring lipid molecules in 
the body and includes both cholesterol and triglycerides.  These molecules are necessary 
for cellular wall structure, digestion of food, production of hormones, as well as energy 
storage.   An appropriate concentration of lipids is naturally synthesized by the liver, 
however genetic mutations and/or lifestyle choices (diet and physical activity) can lead 
to elevated lipid concentrations.   
Clinically, there are four lipid parameters which are routinely measured: low-
density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, total 
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cholesterol (TC) and triglycerides (TG).  LDL cholesterol is known in the general 
population as “bad” cholesterol as it is responsible for transporting cholesterol 
throughout the body. When present in excess, it will deposit cholesterol on the walls of 
arteries, thus leading to atherosclerosis.  The formation of atherosclerosis is a critical risk 
factor for the development of cardiovascular disease 7-10.  HDL cholesterol is routinely 
referred to as “good” cholesterol by the general population as it is responsible for 
transporting excess lipids within the blood vessels back to the liver for recycling.  TC 
represents the cumulative total of all types of cholesterol, including LDL and HDL.  
Finally, TG are fat molecules which, when in excess, can be deposited with LDL 
cholesterol along the walls of arteries leading to atherosclerosis.  TG are also responsible 
for energy storage.   
 In LMICs, the prevalence of hyperlipidemia is typically lower than that of high 
income countries (HICs), however new evidence projects a substantial rise in the near 
future.  In 2008, the WHO reported the global prevalence of elevated cholesterol to be 
39% and an estimated 2.6 million deaths annually to be due to high cholesterol 2.  The 
WHO Africa and Southeast Asia regions had the lowest prevalence rates at 23% and 
29%, respectively.  Kenya, specifically had a prevalence of 26% 11.  However, multiple 
studies are projecting an inevitable rise in the burden of hyperlipidemia for LMICs due 
to its strong correlations with urbanization, western diet, obesity, and rising national 
income, which are increasingly prevalent in LMICs 7, 12, 13.   
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1.2 Current diagnostic barriers for hyperlipidemia 
Hyperlipidemia inherently poses multiple challenges in diagnosing and 
monitoring given its potential for “silent” progression and turnaround time.  Despite its 
status as a significant risk factor for cardiovascular events, most patients are unlikely to 
present with any symptoms 14.  Thus, in LMICs where patients commonly do not present 
to a health facility until their quality of life is significantly affected by a condition 15 , the 
challenge to diagnose hyperlipidemia at an early stage and prevent progression of 
cardiovascular disease becomes even greater.  The current gold standard of diagnosing 
hyperlipidemia is a laboratory-based serum study.  Due to its lack of immediate results, 
patients may also find it challenging to return to the health facility to obtain results and 
medical recommendations given barriers of transportation and related costs. 
Furthermore, the current gold standard requires significant laboratory infrastructure 
and therefore lacks mobility.      
 
1.3 Point of care technology and hyperlipidemia 
In response to the limitations presented by traditional laboratory methods for 
diagnosing a variety of conditions in LMICs, POC technology has been proposed as a 
potentially effective method of delivering diagnostic care 16-18.  Points of care tools 
oftentimes involve mobile handheld devices which can be carried to rural areas that lack 
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laboratory infrastructure.   Results are frequently produced in less than 10 minutes, and 
clinicians are subsequently able to make medical management decisions or seek expert 
consultation within the same patient encounter.  In addition, screening campaigns are 
able to inform patients within their homes of the results and make referrals to the 
appropriate health facility if necessary.  More recently, POC technology has become 
simplified for patients to use at home without assistance of health professionals, thus 
allowing them to circumvent barriers of access to diagnostic services or stigma that may 
prevent them from presenting to a public facility for testing.  However, not all POC 
technology offers all these advantages.  Potential disadvantages for some POC devices 
include: cost, requirement of refrigeration for test reagents, need for laboratory 
infrastructure to house a large bench-top machine or computer, requirement of reliable 
electricity source, need for extensive laboratory training, and lack of quality control 
leading to inaccurate results 16-18.  Thus far in LMICs, several studies have shown 
promising early results for a broad range of pathologies, including diabetes mellitus, 
HIV, hepatitis B, venous thrombosis, and syphilis 4, 19-21.   
In regards to hyperlipidemia, several POC devices have been produced, but with 
varying performance characteristics.  A review of six different POC lipid analyzers 
assessed in high-income countries (HICs) concluded that insufficient evidence exists to 
displace traditional laboratory lipid testing 22.  The model Cholestech LDX (Alere Inc., 
Waltham, United States) had the most promising results matching the accuracy of 
 6 
laboratory lipid testing in several studies 23-25, though not all 26, 27.  However, this model 
requires that individual cartridges not used within 30 days be refrigerated, which is not 
possible in many LMIC settings.  Furthermore, one study showed Cholestech LDX to 
have the highest cost among six different POC lipid diagnostic models 22.   
CardioChek PA (Polymer Technology Systems, Inc., Indianapolis, United States) 
is another model which has a lower cost and does not require refrigeration.  However, it 
has had limited and conflicting results.   In a comparison study of CardioChek PA 
versus Cholestech LDX by Dale et al. 23 in the United States, only Cholestech was able to 
produce a full lipid panel with accuracy comparable to that of the gold standard.  
CardioChek PA was only able to produce triglyceride levels with sufficient accuracy.  
Moreover, CardioChek PA showed poor clinical relevance by consistently 
underestimating the Framingham Risk Score.  A similar comparison study was 
performed by Shephard et al. in Australia which also showed CardioChek performing 
accurately only for triglyceride measurements 28.  However, Panz et al. performed the 
same comparison in South Africa and concluded that both analyzers performed with 
sufficient accuracy with respect to the gold standard 29.  The study did note that higher 
levels of LDL results were underestimated by CardioChek.  While the results across 
studies for CardioCheck PA are conflicting, the only independent study supporting its 
use is from sub-Saharan Africa.  This single study has yet to be reproduced anywhere 
else on the continent. 
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In Kenya, CardioChek PA is readily available and is the only POC lipid analyzer 
that is accessible in Kenya 30, however it has yet to be validated.  In this study, we 
assessed the accuracy of CardioChek PA with respect to traditional laboratory lipid 
testing in western Kenya. 
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2. Methods 
A cross-sectional, prospective study was performed in the catchment area of 
Webuye District Hospital (WDH) of western Kenya. 
2.1 Setting 
Webuye is a town in western Kenya located approximately 400 km northwest of 
the capital, Nairobi.  The area is primarily agricultural and WDH serves a primarily 
rural population with some peri-urban clients.  Farming is the main economic activity.  
Sugar cane is the main cash crop while maize, beans, millet and sorghum are grown for 
subsistence. Small-scale dairy and poultry farming is widely practiced. A paper factory 
and chemical processing plant are located in the adjacent area. Social amenities like 
clean water, sanitation and electricity are not available to the majority of the residents. 
Webuye is also home to the Health and Demographic Surveillance System (HDSS) 
which is a household-level database of approximately 80,000 people living in about 
13,500 households within the Webuye division.   
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Credit: Webuye Health and Demographic Surveillance Site 
 
Figure 1: Map of Webuye Division, home of the Health and Demographic 
Surveillance System (HDSS) 
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2.2 Ethical Considerations 
All patients provided informed consent.  Ethics approval was obtained by the 
Institutional Research Ethics Committee at Moi Teaching and Referral Hospital, which 
includes the research ethics oversight of Webuye District Hospital.  An exemption was 
obtained by Duke University Institutional Review Board to perform the data analysis 
and final report based on a de-identified data set.   
2.3 Sampling and Data Collection 
Adult subjects (n=246) were selected by stratified sampling from the HDSS 
database.  The stratification parameter applied was sub-location within the Webuye 
division, and we then applied simple random sampling to each stratum of adults.  The 
sample size calculation was based on applying the estimated diabetes mellitus 
prevalence of 3% and a confidence interval of +/- 3%, and produced a minimum sample 
size value of 129 subjects.  This value represents the number of subjects required to 
detect a significant difference between the results of the two lipid measuring tools.  The 
determination of significant difference is based on percent bias ranges described below.  
Of note, the prevalence of diabetes mellitus was applied because this study is part of a 
larger study looking at multiple cardiovascular risk factors across the Webuye division.  
Given that diabetes mellitus is expected to have the lowest prevalence among the 
diseases under study, the sample size calculation was based on diabetes.   
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Venous and capillary blood specimens were collected for the laboratory lipid 
testing as well as CardioChek PA analyzer, respectively, by trained laboratory 
technicians.  Patient encounter settings included local health centers as well as local 
schools and churches as to accommodate any transportation challenges for the subjects.  
Two CardioChek PA analyzers were used during the study and each was calibrated.   
CardioCheck PA results were produced at the time of patient encounter, and venous 
samples were transported to the Academic Model Providing Access to Healthcare 
(AMPATH) reference laboratory (ARL) in Eldoret, Kenya.  Delay due to transportation 
of venous samples ranged from 4 to 9 hours.  During this time period, specimens were 
stored in an ice box.   The ARL uses COBAS analyzers (Roche Diagnostics, Basel, 
Switzerland) for lipid testing, and all LDL values are calculated, as opposed to 
measured.  The ARL uses established Standard Operating Procedures which have been 
reviewed by a site assessment team from Pharmaceutical Product Development Ltd.  
Furthermore, the ARL is certified by the Kenyan Medical Licensing Board, and is 
accredited by the NIH Division of AIDS international laboratory standardization 
program.  
2.4 Statistical analysis 
Statistical analysis was based on the methods established by the Working Group 
on Lipoprotein Measurements of the National Cholesterol Education Program (NCEP), 
which sought to establish a standard approach for assessing the accuracy and precision 
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in measuring LDL, HDL, TC, and TG 31, 32.  These regulations were subsequently 
submitted to and published by the National Heart, Lung, and Blood Institute of the 
National Institute of Health (NIH) 31.  As per NCEP guidelines, the diagnostic accuracy 
of a novel method for measuring blood lipids should be judged by calculating the 
percent bias.  Percent bias is defined as the mean of the difference between the values 
reported (experimental and reference) when calculated as a percent of the reference 
value: 
Percent bias =  
where  is the reported “reference” value of the gold standard method,  is the 
reported “experimental” value of the method under study, and n is the sample size for a 
given parameter.  The acceptable bias ranges are different for each of the four lipid 
parameters and have been described by the NCEP (see Table 1).  A bias value within this 
range would indicate that the method being studied has accuracy not significantly 
different from that of routine use of the gold standard laboratory method.  Additionally, 
we calculated the proportion of subjects whose individual percent bias values were 
outside the acceptable range. 
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Table 1: Standards for Accuracy of Lipid Measurements by NCEP Guidelines 
Parameter   Bias (%) 
LDL* Cholesterol 
 
≤±3 
HDL+ Cholesterol 
 
≤±5 
Total Cholesterol 
 
≤±5 
Triglycerides 
 
≤±4 
*LDL=Low density lipoprotein 
+HDL=High density lipoprotein 
The absolute percent bias was determined in a nearly identical fashion as the 
methods of determining percent bias with the exception of taking the absolute value of 
the difference between the values reported (experimental and reference): 
Absolute percent bias =  
No standard values or guidelines for absolute percent bias are provided by NCEP. 
The clinical relevance of inaccurate results was assessed by identifying the 
misclassification rate of each lipid panel parameter.  Misclassification rate is determined 
by calculating the proportion of subjects that are categorized by the POC analyzer into a 
risk group that is different from the risk group categorized by the gold standard.  The 
risk groups were defined by value ranges from the Adult Treatment Panel III (ATP III) 
report 33 (see Table 2).   The ATP III guidelines seek to establish correlations between 
rising lipid parameter values and risk of coronary heart disease.  These guidelines are 
routinely used in the clinical setting in order to determine the appropriate step in 
treating or preventing hyperlipidemia.  Thus, the misclassification rate is a reflection of 
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the frequency in which a physician may be misguided by the POC results when making 
medical management decisions. 
Table 2: Adult Treatment Panel III (ATP III) Risk categories by lipid 
parameter 
Risk group* LDL (mg/dL) HDL (mg/dL) TC (mg/dL) TG (mg/dL) 
Optimal <100 >40 <200 <150 
Above 
optimal 
≥100 and <130 -- -- -- 
Borderline 
high 
≥130 and <160 ≥50 and <60 
≥200 and 
<240 
≥150 and 
<200 
High ≥160 ≥60 ≥240 ≥200 
*The risk groups and their respective values are applicable towards adults who 
otherwise do not have other risk factors for coronary heart disease. 
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3. Results 
3.1 Accuracy per NCEP guidelines 
The accuracy of CardioChek PA in relation to venous laboratory testing was 
markedly low.  As seen in Table 4, the percent bias values of all lipid parameters were 
outside of the acceptable ranges with the exception of that of triglycerides (0.03%).  
However, the absolute percent bias for triglycerides was 27.7%, and 85% (n=206) of 
subjects had triglyceride results outside of the accepted NCEP ranges (Table 5).  All 
other parameters resulted in higher proportions of subjects with results outside of the 
acceptable range.  LDL cholesterol had the highest proportion at 98% (n=235).   
Furthermore, 38% (n=98) of total cholesterol values and 33% (n=80) of triglyceride values 
from CardioChek PA were “undetectable.”   None of the results produced by the 
laboratory method were “undetectable.” 
       Table 3: Percent bias for lipid measurements via CardioChek PA 
Parameter 
  
Bias, %                
[95% CI]   
Absolute bias, % 
[95% CI] 
LDL Cholesterol 
 
-25.9 [-29.7,-22.1] 
 
33.5 [30.9, 36.2] 
HDL Cholesterol 
 
-8.2 [-12.9,-3.6] 
 
24.7 [21.1, 28.3] 
Total Cholesterol 
 
-15.9 [-19.8,-12.1] 
 
24.3 [21.1, 27.4] 
Triglycerides 
 
0.03 [-8.6,8.6] 
 
27.7 [19.8, 35.5] 
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Table 4: Proportion of subjects outside of NCEP percent bias standards 
Parameter   
Proportion outside of 
acceptable range 
LDL Cholesterol 
 
98% 
HDL Cholesterol 
 
86% 
Total Cholesterol 
 
90% 
Triglycerides 
 
85% 
 
3.2 Clinical accuracy 
The misclassification rate of CardioChek PA varied by parameter and largely 
supported previous findings in the literature which noted a tendency for 
underestimation of the true value (Table 6).  The total misclassification rates ranged 
from 0.8% (triglycerides) to 36.7% (LDL cholesterol).  Within each parameter, the 
misclassification rate was generally higher for the higher value categories within each 
parameter.   
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Table 5: Misclassification rate by CardioChek PA within specific ranges of 
lipid results 
  
No. Subjects 
(lab method) 
No. Subjects 
misclassified 
(POC method) 
Misclassification 
rate (%) 
LDL (mg/dL) 
   <100 141 2 1.4 
≥100 and <130 74 63 85.1 
≥130 and <160 16 14 87.5 
≥160 9 9 100.0 
Total 240 88 36.7 
    HDL (mg/dL) 
   <40 49 13 26.5 
≥40 and <60 128 72 56.3 
≥60 66 28 42.4 
Total 243 113 46.5 
    TC (mg/dL) 
   <200 208 1 0.5 
≥200 and <240 29 25 86.2 
≥240 6 6 100.0 
Total 243 32 13.2 
    TG (mg/dL) 
   <150 233 2 0.9 
≥150 and <200 6 5 83.3 
≥200 3 1 33.3 
Total 242 8 3.3 
 
Figure 2 displays a line graph of paired values. Each pair includes a group mean 
laboratory LDL cholesterol result as well as the respective group mean POC result.  The 
groups were formed by establishing 18 evenly distributed cutoff points to encompass 
the entire range of laboratory LDL cholesterol values.  The figure illustrates the under-
estimation of the true LDL values by CardioChek PA among higher LDL values.   
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Figure 2: Comparison of LDL cholesterol values between laboratory results 
and respective POC results 
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4. Discussion 
4.1 Accuracy of CardioChek PA 
This was the first study of the accuracy of the CardioChek PA POC device for 
blood lipid measurement in western Kenya.  Our analysis of the accuracy of this device 
using methods and guidelines recommended by the NCEP showed that CardioChek PA 
produced unacceptable results in regards to its accuracy of real-time lipid 
measurements.   
Low density lipoprotein, HDL and TC were substantially outside of the 
acceptable percent bias range while TG percent bias was within the acceptable range.  
The seemingly positive outcome for TG measurements, however, must be considered in 
the context of the results of the absolute bias and highlights the potential for misleading 
results when using percent bias alone. For example, triglyceride measurements 
produced an absolute bias greater than that of HDL cholesterol and total cholesterol 
despite being the only parameter within the accepted range of percent bias.  
Furthermore, the percent bias confidence intervals of triglyceride show that CardioChek 
PA has the potential for equally over- and under-estimating the true triglyceride value 
while consistently underestimating the true values of LDL, HDL and TC.  A similar 
trend across parameters was also identified by Dal, et al. when assessing the 
CardioChek PA analyzer 23.  By equally over- and under-estimating the true value, the 
cumulative difference from the true value trends towards zero regardless of the 
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magnitude of the individual over- and under-estimations.  This potential for deception is 
relevant to the case of triglycerides in that despite having an acceptable percent bias, 
85% of the individual percent bias values were outside of the NCEP acceptable ranges.   
The misclassification rate was generally greater for those subject groups with 
higher lipid and lipoprotein values.   This finding is consistent with prior studies 
showing that CardioChek PA is prone to underestimating the true value of cholesterol 
levels.  Thus, those subjects in the highest risk categories for cardiovascular 
complications (based on LDL, TG, and TC levels) will be more likely to be misclassified 
into a lower risk category.  For example, an LDL cholesterol level of 160 mg/dL is an 
important threshold which impacts clinical decision making for preventive and 
therapeutic measures 33. Having an LDL level this high usually implies a markedly 
increased risk of developing coronary heart disease, and therefore warrants more 
aggressive treatment measures.  In this study, 100% of subjects with true LDL 
cholesterol values ≥160 mg/dL were misclassified into a lower risk classification (Table 
6).  Therefore, screening high risk patients with CardioChek will oftentimes produce 
misleading results.  This shortcoming precludes CardioChek PA from being a clinically 
reliable tool in our setting.  The high rate of “undetectable” values by CardioChek PA 
also adds to the clinical challenges of the instrument.  In comparison to discrete 
numerical values consistently produced by the gold standard, “undetectable” results are 
less clinically valuable when making management decisions.  
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Less than 5% (n=11) of all samples were non-fasting.  Recent studies have noted 
the insignificance of fasting versus non-fasting lipid measurements 34, 35.  Thus, the 
minimal quantity of heterogeneity of specimens with respect to fasting status is unlikely 
to create a significant impact on the results. 
4.2 Limitations 
Limitations of the study included the lack of precision analysis, size limitations, 
and the comparison of capillary versus venous samples.   Adequate data were not 
collected to be able to do precision analysis, thus a complete validation study could not 
be performed.  As per NCEP guidelines, assessment of precision in lipid measurements 
requires multiple runs of each set of samples.  The variation both between runs as well 
as within each run is then assessed 31, 32.  However, the clear shortcomings in accuracy 
alone deem the diagnostic tool inappropriate for our setting.  In regards to size, the 
study was only based on a single center which questions reproducibility of results, and 
the sample size was limited such that lipid level categories of higher risk were 
substantially smaller than the other categories.  Lastly, there is conflicting data regarding 
the comparability of capillary and venous blood samples with respect to lipids and 
lipoproteins 25, 36.   The difference in results from prior studies may be due to specimen 
collection technique.   
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4.3 Conclusion 
This study highlights critical shortcomings of using the CardioChek PA POC 
instrument for assessing blood lipid levels in rural western Kenya.  Its poor test 
characteristics were also shown in other geographic areas of greater resource 
availability.  This diagnostic instrument’s lack of accuracy in addition to its unacceptable 
clinical applicability nullifies any perceived advantage of this particular POC device.   
This study shows that all novel technology with great potential utility should 
still be independently validated in the relevant setting. Despite relative success in its 
applicability in South Africa, CardioChek PA did poorly in Kenya.  Findings from a 
LMIC setting cannot be generalized uniformly even within the sub-Saharan Africa 
region.  Additionally, further studies assessing a broad spectrum of POC lipid devices 
would be of value to assess the broader applicability of POC lipid diagnostics in a 
resource-limited setting. The shortcomings of CardioChek PA may not be particularly 
true for other analyzers in this setting.  The potential advantages of POC technology for 
critical diseases, such as hyperlipidemia, warrant a continued pursuit of instrument 
validation in this setting. 
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